SLS
Sellas Life Sciences Group
$13.49
−$0.46 (−3.3%)Sep 10, 2026
Key metrics
The numbers that frame SLS today
- Market cap
- $2.72B
- P/E (TTM)
- -83.9
- EV / FCF
- -91.0
- ROIC
- 3,321.7%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $1.39
- 52wk High
- $15.88
Growth
Revenue and earnings trend for SLS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SLS
Is Sellas Life Sciences Group a good buy?
Hold. Sellas Life Sciences Group has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Sellas Life Sciences Group is selling at a high price.
What is the market capitalization of SLS?
Sellas Life Sciences Group's market capitalization is $2.72B.
What is the P/E ratio for SLS stock?
Sellas Life Sciences Group's current P/E ratio is -83.9.
What is the 52-week high for SLS stock?
The 52-week high for Sellas Life Sciences Group is $15.88. The current close of $13.49 is 15% below that high.
What is the 52-week low for SLS stock?
The 52-week low for Sellas Life Sciences Group is $1.39. The current close of $13.49 is 870.5% above that low.
Does SLS stock pay dividends?
Sellas Life Sciences Group does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SLS?
Sellas Life Sciences Group's Debt / Equity ratio is 0.01.